The Food and Drug Administration granted breakthrough therapy designation to Arrowhead Pharmaceuticals' plozasiran drug to treat severe hypertriglyceridemia. The designation expedites the development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback